Neuroone Medical Technologies is trading at $1.80 (5.9% up) after positive physician-reported outcomes from a Mayo Clinic study evaluating the company’s brain ablation device for epilepsy.
- The move follows a 5.9% rally in yesterday’s after-hours session, with momentum carrying over into today's trading.
- Investor enthusiasm is driven by encouraging clinical results regarding the efficacy of the company's neurological device in treating epilepsy.